Carnosine and Retinol Synergistically Inhibit UVB-Induced PGE₂ Synthesis in Human Keratinocytes through the Up-Regulation of Hyaluronan Synthase 2.

IF 3 3区医学 Q2 PHARMACOLOGY & PHARMACY

Biomolecules & Therapeutics Pub Date : 2024-09-01 Epub Date: 2024-08-02 DOI:10.4062/biomolther.2023.226

In Guk Park, Sun Hee Jin, Seungchan An, Min Won Ki, Won Seok Park, Hyoung-June Kim, Yongjoo Na, Minsoo Noh

{"title":"Carnosine and Retinol Synergistically Inhibit UVB-Induced PGE2 Synthesis in Human Keratinocytes through the Up-Regulation of Hyaluronan Synthase 2.","authors":"In Guk Park, Sun Hee Jin, Seungchan An, Min Won Ki, Won Seok Park, Hyoung-June Kim, Yongjoo Na, Minsoo Noh","doi":"10.4062/biomolther.2023.226","DOIUrl":null,"url":null,"abstract":"Skin aging results from complex interactions of intrinsic and extrinsic factors, leading to structural and biochemical changes such as wrinkles and dryness. Ultraviolet (UV) irradiation leads to the degradation of hyaluronic acid (HA) in the skin, and the with fragmented HA contributes to inflammation. This study revealed that the synergistic combination of carnosine and retinol (ROL) increases HA production in normal human epidermal keratinocytes (NHEKs) by upregulating hyaluronan synthase 2 (HAS2) gene transcription. Simultaneously, the combined treatment of carnosine and ROL significantly attenuates UVB-induced prostaglandin E2 (PGE2) synthesis in NHEKs. A significant correlation exists between the increase of HA synthesis and the inhibition of PGE2 production. This study suggested that combined treatment of carnosine and ROL can improve skin aging phenotypes associated with UVB irradiation.","PeriodicalId":8949,"journal":{"name":"Biomolecules & Therapeutics","volume":" ","pages":"635-639"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11392658/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4062/biomolther.2023.226","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Skin aging results from complex interactions of intrinsic and extrinsic factors, leading to structural and biochemical changes such as wrinkles and dryness. Ultraviolet (UV) irradiation leads to the degradation of hyaluronic acid (HA) in the skin, and the with fragmented HA contributes to inflammation. This study revealed that the synergistic combination of carnosine and retinol (ROL) increases HA production in normal human epidermal keratinocytes (NHEKs) by upregulating hyaluronan synthase 2 (HAS2) gene transcription. Simultaneously, the combined treatment of carnosine and ROL significantly attenuates UVB-induced prostaglandin E₂ (PGE₂) synthesis in NHEKs. A significant correlation exists between the increase of HA synthesis and the inhibition of PGE₂ production. This study suggested that combined treatment of carnosine and ROL can improve skin aging phenotypes associated with UVB irradiation.

查看原文本刊更多论文

卡诺辛和视黄醇通过上调透明质酸合成酶 2 协同抑制 UVB 诱导的人角质形成细胞中 PGE2 的合成

皮肤老化是内在和外在因素复杂相互作用的结果，导致结构和生化变化，如皱纹和干燥。紫外线（UV）照射会导致皮肤中的透明质酸（HA）降解，而透明质酸降解后的碎片又会引发炎症。这项研究发现，肌肽和视黄醇（ROL）的协同作用可通过上调透明质酸合成酶 2（HAS2）基因转录，增加正常人表皮角质细胞（NHEKs）的 HA 产量。同时，肌肽和 ROL 的联合治疗可显著减少 UVB 诱导的 NHEKs 中前列腺素 E2（PGE2）的合成。HA 合成的增加与 PGE2 生成的抑制之间存在明显的相关性。这项研究表明，肌肽和 ROL 的联合治疗可改善与 UVB 照射相关的皮肤老化表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomolecules & Therapeutics 医学-药学

CiteScore

6.60

自引率

8.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomolecules & Therapeutics (Biomolecules & Therapeutics) (Print ISSN 1976-9148, Online ISSN 2005-4483) is an international, peer-reviewed, open access journal that covers pharmacological and toxicological fields related to bioactive molecules and therapeutics. It was launched in 1993 as "The Journal of Applied Pharmacology (ISSN 1225-6110)", and renamed "Biomolecules & Therapeutics" (Biomol Ther: abbreviated form) in 2008 (Volume 16, No. 1). It is published bimonthly in January, March, May, July, September and November. All manuscripts should be creative, informative, and contribute to the development of new drugs. Articles in the following categories are published: review articles and research articles.